Terms ending in 2031
Every in-force patent on AstraZeneca AB's record whose computed term ends in 2031, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,535,662 | Apyrase Therapy for Bleeding Conditions In force · High confidence | Apt Therapeutics Inc. | In force | High confidence | |
| US 8,771,683 | Therapeutic Apyrase Constructs, Apyrase Agents, and Production Methods In force · High confidence | Apt Therapeutics Inc. | In force | High confidence | |
| US 8,242,044 | Process and Catalyst In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 8,399,460 | Chromenone Derivatives In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 9,220,698 | Method for Delivering A Pharmaceutical Composition to Patient in Need Thereof In force · High confidence | Horizon Therapeutics USA, Inc. | In force | High confidence | |
| US 9,493,565 | Targeted Binding Agents Against B7-H1 In force · Medium confidence | MedImmune Limited | In force | Medium confidence | |
| US 8,225,790 | Inhaler 624 In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 8,986,951 | Tear Lipocalin in Muteins Binding IL-4 R Alpha In force · High confidence | Pieris Pharmaceuticals GmbH | In force | High confidence | |
| US 10,232,014 | Tear Lipocalin Muteins Binding IL-4 R Alpha In force · Low confidence | Pieris Pharmaceuticals GmbH | In force | Low confidence | |
| US 8,252,802 | Chemical Compounds In force · High confidence | AstraZeneca AB | In force | High confidence | |
| 8 more term ends in 2031 · Pro | |||||
10 of 18 patents shown. Soonest term end first, then patent number.
Pro members see all 18.
10 of these are in force and held by AstraZeneca AB.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.